<DOC>
	<DOCNO>NCT02298387</DOCNO>
	<brief_summary>This open-label Phase 1 dose escalation expansion study OMP-305B83 subject previously treat solid tumor . Study include dose escalation phase expansion phase . Subjects assess safety , immunogenicity , pharmacokinetics , biomarkers , efficacy .</brief_summary>
	<brief_title>A Phase 1 Study OMP-305B83 Subjects With Solid Tumors</brief_title>
	<detailed_description>This open-label Phase 1 dose escalation expansion study OMP-305B83 subject previously treat solid tumor . Study include dose escalation phase expansion phase . Subjects assess safety , immunogenicity , pharmacokinetics , biomarkers , efficacy .</detailed_description>
	<mesh_term>Antibodies , Bispecific</mesh_term>
	<criteria>1 . Subjects must histologically confirm malignancy metastatic unresectable remain standard curative therapy therapy demonstrate survival benefit must ineligible receive therapy and/or decline therapy . In addition , subject must tumor least 1 cm single dimension radiographically apparent CT MRI . 2 . FFPE tumor tissue either fresh core needle biopsied archive ( two FFPE core prefer whenever possible ) require participation study . If fresh tissue obtain , core biopsy must do least â‰¥7 day prior Day 0 . 3 . Subjects must receive last chemotherapy , nonantiVEGF biologic , investigational therapy least 4 week prior enrollment , 6 week last regimen include BCNU mitomycin C , 8 week last regimen antiVEGF therapy 4 . Age &gt; 21 year 5 . ECOG performance status &lt; 2 6 . Life expectancy 3 month 7 . Subjects must adequate organ marrow function define : Absolute neutrophil count &gt; 1000/mL ( without colony stimulate factor within last 2 week ) Hemoglobin &gt; 10.5 g/dL ( without erythropoietin blood transfusion within last 2 week ) Platelets &gt; 100,000/mL ( without platelet transfusion within last 2 week ) Total bilirubin &lt; 1.5 X institutional upper limit normal ( ULN ) AST ( SGOT ) ALT ( SGPT ) &lt; 2 X institutional ULN ( subject hepatic metastasis &lt; 5 X institutional ULN ) INR PTT within 1.5 X institutional ULN Proteinuria &lt; trace Creatinine &lt; 1.5 X institutional ULN OR Creatinine clearance &gt; 60 mL/min/1.73 m2 subject creatinine level institutional normal 8 . Women childbearing potential must prior hysterectomy negative serum pregnancy test use adequate contraception prior study entry must agree use adequate contraception study entry least 6 month discontinuation study drug . Men must also agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry study entry least 6 month discontinuation study drug . Should woman enrol study female partner man enrol study become pregnant suspect pregnant participate study within 6 month discontinuation study , inform Investigator immediately . 9 . Ability understand willingness sign write informed consent document 1 . Subjects receive investigational agent 2 . Subjects receive antiDLL4 antibody , antiDLL4/VEGF bispecific antibody Subjects receive prior antiVEGF therapy eligible , unless residual serious adverse event related antiVEGF therapy . 3 . Subjects history abdominal fistula , gastrointestinal perforation , intraabdominal abscess ; clinical sign symptom GI obstruction and/or requirement parenteral hydration nutrition . In addition , subject know clinically significant gastrointestinal disease include , limited , inflammatory bowel disease . 4 . Subjects brain metastasis ( subject must CT scan MRI head within 28 day prior enrollment rule brain metastasis ) , uncontrolled seizure disorder , active neurologic disease 5 . History significant allergic reaction attribute humanized human monoclonal antibody therapy 6 . Significant intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement 7 . Pregnant woman nurse woman 8 . Subjects know HIV infection 9 . Known bleed disorder coagulopathy 10 . Subjects receive heparin , warfarin , similar anticoagulant , except subject low molecular weight heparin DVT/PE prophylaxis . Note : Subjects may receive lowdose aspirin and/or nonsteroidal antiinflammatory agent . 11 . Subjects ascites pleural effusion require drainage within last 28 day . 12 . Subjects blood pressure &gt; 140/90 mmHg . 13 . Subjects squamous cell carcinoma lung 14 . Subjects undergone major surgery within last 6 week 15 . New York Heart Association Classification II , III , IV ( see APPENDIX D )</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>